SGLT2 battleground takes shape on ADA readout
This article was originally published in Scrip
Executive Summary
The battle lines are becoming a bit clearer in the SGLT2 inhibitor drug class following the release of new clinical data at the recent American Diabetes Association meeting in Chicago.